TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04793386

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: carotid ultrasound
Description: Every time checking pulse, evaluate the carotid artery compressibility and pulsatility by ultrasound
Study: NCT06374212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: 900mg maintenance dose every 4 weeks for 12 weeks then 600mg loading dose every 4 weeks until week 20
Study: NCT05492214

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (30s)
Description: The same as that stated in arm descriptions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (60s)
Description: The same as that stated in arm descriptions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (90s)
Description: The same as that stated in arm descriptions.
Study: NCT06318429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stretching exercise group
Description: stretching exercise group
Study: NCT05851586

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supervised exercise + home exercise program
Description: The supervised exercise + home exercise program group will receive a written home exercise program with general stretching and strengthening exercises for the neck, thoracic spine, lumbar spine, shoulder and hand/wrist. They will also be provided with two supervised exercise sessions per month delivered in a group setting in order to ensure proper performance of the home exercise programs.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise program only
Description: The home exercise program only group will receive a written home exercise program with general stretching and strengthening exercises for the neck, thoracic spine, lumbar spine, shoulder and hand/wrist, without any supervised guidance on exercise performance.
Study: NCT06376513

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation
Description: Evaluation of the manipulation abilities of patients with penile prostheses Evaluation of the rigidity of erections with penile prosthesis, the patient and partner's sexual satisfaction, the satisfaction related to pump manipulation
Study: NCT05486260

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DMB lowest dose
Description: Intake of 150 mg of DMB
Study: NCT05840510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: KRAS G12C inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Sirolimus
Description: mTOR inhibitor
Study: NCT05486260

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DMB highest dose
Description: Intake of 300 mg of DMB

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Strawberry lyophilisate
Description: Intake of 300 mg of strawberry lyophilisate
Study: NCT06015542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: Elranatamab will be administered as monotherapy for six cycles of 28 days. Elranatamab 76 mg will be administered QW with a 2-step-up priming dose regimen administered during the first week (12 mg D1 and 32 mg D4).
Study: NCT05859542

Intervention type: DEVICE
Intervention: Videolaryngoscope first
Description: started the session with 3 intubations using the videolaryngoscope

Intervention type: DEVICE
Intervention: Direct laryngoscope first
Description: started the session with 3 intubations using the Direct laryngoscope
Study: NCT05865314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimisation of nutrition therapy coupled with early mobilisation
Description: Optimisation of nutrition therapy coupled with early mobilisation with:~* Optimisation of nutrition therapy during ICU stay~* Optimisation of physiotherapy during ICU stay~* Better communication and closer collaboration between physiotherapy and nutrition teams.~* Optimisation of continuity of the care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patients will receive nutritional therapy and mobilisation according to local standard procedures.
Study: NCT06316882

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Screening endoscopy
Description: We perform upper endoscopy, when the patient authorizes it, during their screening colonoscopy
Study: NCT05490225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ark
Description: The Ark will be surgically implanted at the access site in subjects undergoing routine hemodialysis. The Ark is expected to provide a target to aid in long-term cannulation success.
Study: NCT06552104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACUPRESSURE APPLI ACUPRESSURE APPLICATION
Description: Pre-test data were collected from participants who met the inclusion criteria and volunteered to participate in the study by researcher BI in the LDP rooms during the latency period of labor. Post-test data were obtained by the same researcher 16 hours after the cesarean section. Data were obtained using the Personal Information Form, Episiotomy Evaluation Form (EEF), Visual Analog Scale (VAS), and Spielberger Manual for State-Trait Anxiety Inventory (STAI).
Study: NCT05606679

Intervention type: GENETIC
Intervention: Analysis combinations of maternal KIR and HLA-C genotypes
Description: Analysis of combinations of maternal KIR and HLA-C genotypes of the egg donor and fetus (based on the genotypes of the donor and male partner), as well as different HLA-F SNP genotypes of the recipients
Study: NCT04837534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling group
Description: In this group after the children have been examined, treatment plan and follow up schedule been advised by a pediatric ophthalmologist, parents/guardians along with the child will receive counseling from a trained counselor as per the set counseling protocol in every follow-up visits and will also be provided with the disease-specific information leaflets as an additional information material before the child is discharged from the department.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS and phone call reminder group
Description: In this group after the children have been examined, treatment plan, and the follow-up schedule been advised, they will be discharged from the department but later they will receive reminders through short messaging text (SMS) and phone calls as per the set protocol.
Study: NCT04389580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Isotretinoin plus Tamoxifen
Description: 20 mg PO (by mouth) twice daily for 14 days~13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days starting after three days of taking tamoxifen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aerosolized Isotretinoin plus Tamoxifen
Description: 20 mg PO (by mouth) twice daily for 14 days~Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days starting after three days of taking tamoxifen
Study: NCT04996264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varespladib Methyl
Description: Varespladib-methyl (LY333013) is an IR, oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration. Scaled pediatric doses of varespladib-methyl (LY333013) are supplied as 50 mg IR capsules for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The oral placebo is supplied as a white film-coated oval tablet to match the appearance of the varespladib-methyl 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate.~Placebo for scaled pediatric dosing is supplied as an IR capsule to match the varespladib-methyl 50 mg capsule, and contains the excipients lactose monohydrate, microcrystalline cellulose, and magnesium stearate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care (SOC)
Description: SOC (including antivenom) will continue to be administered throughout the subject's participation in the study according to the protocol and the judgment of the Investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care (SOC)
Description: SOC (including antivenom) will continue to be administered throughout the subject's participation in the study according to the protocol and the judgment of the Investigator.
Study: NCT05245825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flaxseed
Description: A total of 30 g of ground flaxseed per day divided into two portions of 15 grams each, subjects will be asked to take 15 g in the morning and 15 g in the night dissolved in 400 ml of water. They will receive a dietary plan with a distribution of 20-30% of protein, 25-30% of lipids, and 40 to 45% of carbohydrates.
Study: NCT06197932

Intervention type: OTHER
Group type: OTHER
Intervention: Routine exercise and running training
Description: impact of a 4-week running training program on physical performance variables in a control group comprising 15 participants. The control group exclusively underwent running training, and measurements were taken for variables such as the strength of the big toe of both right and left feet using a hip and toe dynamometer (measured in kilograms). Additionally, assessments included vertical jump height and horizontal jump distance (both measured in centimeters), balance using the Y-balance test, and agility via the T-test. All measurements were conducted with standardized equipment, both before and after the training period. se physical performance indicators.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Big Toe Strengthening Exercise
Description: impact of a 4-week intervention involving toe-strengthening exercises and concurrent running training on 15 participants. Pre-assessment measurements included big toe strength, vertical and horizontal jump heights, Y-balance for balance, and T-tests for agility. Following pre-assessment, participants followed a structured toe-strengthening protocol, performing 15 repetitions in three sets twice a day for three weeks. Post-intervention measurements, using the same units and instruments, aim to reveal the effects of the intervention on specified physical variables. This research provides insights into the potential benefits of combining toe-strengthening exercises with running training for enhanced physical performance.
Study: NCT05245825

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary plan
Description: Dietary plan with a distribution of 20-30% of protein, 25-30% of lipids, and 40 to 45% of carbohydrates, controlled consumption of alpha-linolenic acid (no more than 6.8 g/day, the amount provided by 30 g of flaxseed).
Study: NCT06399029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Topical Cream
Description: Ruxolitinib cream will be applied topically twice daily on up to 20% of the body surface over 12 weeks in patients with lichenoid skin toxicity under anti PD1 treatment.
Study: NCT05018325

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy with 6 minute withdrawal
Description: Withdrawal time will be determined using a digital stopwatch by the nursing staff.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy 9 minute withdrawal
Description: Withdrawal time will be determined using a digital stopwatch by the nursing staff.
Study: NCT05823116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin Continuous Infusion
Description: A precision drug dosing platform will be used to determine the empiric dosing regimen and the dosing parameter targeted will be an area-under-the-curve (AUC) of 500 mg⸱hr/L (range 400-600 mg⸱hr/L). The total daily dose is infused over a period of 24 hours.
Study: NCT05018325

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy 12 minute withdrawal
Description: Withdrawal time will be determined using a digital stopwatch by the nursing staff.
Study: NCT05823116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin Intermittent Infusion
Description: A precision drug dosing platform will be used to determine the empiric dosing regimen and the dosing parameter targeted will be an area-under-the-curve (AUC) of 500 mg⸱hr/L (range 400-600 mg⸱hr/L). The dose is infused at rates of 1 gram per hour in every 8, -12, or -24 hour intervals.
Study: NCT04581317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: meals
Description: Participants will receive meals delivered to them by the Meals oN wheels(MOW) program for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: meals
Description: Participants will receive meals delivered to them by the Meals oN wheels(MOW) program for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: meals
Description: Participants will receive meals delivered to them by the Meals oN wheels(MOW) program for 6 weeks.
Study: NCT05601544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS 1-Day
Description: Sphere CONTROL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS 1-Day
Description: Sphere CONTROL
Study: NCT04581317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AES 8 basic usage
Description: For the second 6 weeks, participants will continue to have meal deliveries and will now have the AES 8 device which can be used by the cognitively impaired participant and their caregiver. AES 8 devices will be installed in participant's homes by the study team and participants will be given basic instructions on using the device as well as a one-page handout that will include instructions on how to use and maintain privacy with their device. The study staff will continue to call twice a week to ask the 5 questions. At the end of the 6 weeks, a study team member will make an in-person visit to the participants' homes to measure FFP, MHS, CES-D, MOCA, ADL/IADLs, NSI, ZCBI, and TAM.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AES 8 advanced usage
Description: In the third 6 weeks, the participants will continue to have meal deliveries and the AES 8 will be upgraded to provide an active intervention by asking the twice a week 5 questions through the device. The questions should be answered by the cognitively impaired older adult using the device, though the caregiver can still use the device for other basic services. The participant will be able to answer the questions verbally or by touch screen options displayed on the device.At the end of the 6 weeks, a study team member will make an in-person visit to the participants' homes to measure FFP, MHS, CES-D, MOCA, ADL/IADLs, NSI, ZCBI, and TAM.
Study: NCT05485402

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Refined olive oil (38.6 mg hydroxytyrosol and tyrosol/kg oil)
Description: The dosage will be 30 ml/day of refined olive oil (38.6 mg hydroxytyrosol and tyrosol/kg oil) used as a dressing (without heat).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Virgin olive oil rich in phenolic compounds (156 mg hydroxytyrosol and tyrosol/kg oil)
Description: The dosage will be 30 ml/day of virgin olive oil rich in phenolic compounds (156 mg hydroxytyrosol and tyrosol/kg oil) used as a dressing (without heat).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Virgin olive oil rich in phenolic compounds (156 mg hydroxytyrosol and tyrosol/kg oil)
Description: The dosage will be 30 ml/day of virgin olive oil rich in phenolic compounds (156 mg hydroxytyrosol and tyrosol/kg oil) used as a dressing (without heat).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: The dosage will be 7,5 g/day of maltodextrin.
Study: NCT05364190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Canagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.
Study: NCT05485402

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maltodextrin
Description: The dosage will be 7,5 g/day of maltodextrin.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic (FOS and inulin)
Description: The dosage will be 7,5 g/day of prebiotic supplement (FOS and inulin).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional and physical activity recommendations
Description: The nutritional recommendations are based on DASH diet and foods rich in protein (in particular, leucine) and vitamin D, polyunsaturated acids, phosphorus and iron. The physical activity recommendations are 150 min/week of physical activity, with at least two sessions dedicated to the development of motor strength.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional and physical activity recommendations
Description: The nutritional recommendations are based on DASH diet and foods rich in protein (in particular, leucine) and vitamin D, polyunsaturated acids, phosphorus and iron. The physical activity recommendations are 150 min/week of physical activity, with at least two sessions dedicated to the development of motor strength.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional and physical activity recommendations
Description: The nutritional recommendations are based on DASH diet and foods rich in protein (in particular, leucine) and vitamin D, polyunsaturated acids, phosphorus and iron. The physical activity recommendations are 150 min/week of physical activity, with at least two sessions dedicated to the development of motor strength.
Study: NCT06403683

Intervention type: DIAGNOSTIC_TEST
Intervention: WaLIDD score / Insomnia Severity Index (ISI) / International Physical Activity Questionnaire (Short-form) / Six-Minute Walk Test
Description: Case control trial study

Intervention type: DIAGNOSTIC_TEST
Intervention: WaLIDD score / Insomnia Severity Index (ISI) / International Physical Activity Questionnaire (Short-form) / Six-Minute Walk Test
Description: Case control trial study
Study: NCT05414084

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral (poly)phenol challenge test (OPCT)
Description: Nutritional challenge with standardized (poly)phenol-rich tablets
Study: NCT06110247

Intervention type: DEVICE
Intervention: NIRS
Description: After the positions of the renal NIRS probes are confirmed by ultrasonography, the average value of the three measurements will be taken and the regional oxygen saturation index (rSO2) will be accepted as the initial value.

Intervention type: DEVICE
Intervention: NIRS
Description: After the positions of the renal NIRS probes are confirmed by ultrasonography, the average value of the three measurements will be taken and the regional oxygen saturation index (rSO2) will be accepted as the initial value.

Intervention type: DEVICE
Intervention: NIRS
Description: After the positions of the renal NIRS probes are confirmed by ultrasonography, the average value of the three measurements will be taken and the regional oxygen saturation index (rSO2) will be accepted as the initial value.

Intervention type: OTHER
Intervention: Taking a blood sample
Description: Pre- and Postoperative hemoglobin (Hb), hematocrit (Htc), leukocyte (WBC), blood urea nitrogen (BUN), serum creatinine (sCr), procalcitonin, interleukin-6 and CRP values will be recorded.

Intervention type: OTHER
Intervention: Taking a blood sample
Description: Pre- and Postoperative hemoglobin (Hb), hematocrit (Htc), leukocyte (WBC), blood urea nitrogen (BUN), serum creatinine (sCr), procalcitonin, interleukin-6 and CRP values will be recorded.
Study: NCT04953078

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baiya SARS-CoV-2 Vax 1
Description: Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 1 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baiya SARS-CoV-2 Vax 1
Description: Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 1 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baiya SARS-CoV-2 Vax 1
Description: Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 1 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baiya SARS-CoV-2 Vax 1
Description: Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 1 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baiya SARS-CoV-2 Vax 1
Description: Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 1 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baiya SARS-CoV-2 Vax 1
Description: Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 1 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)
Study: NCT05601544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS MAX 1-Day
Description: Sphere TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS MAX 1-Day
Description: Sphere TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS Multifocal
Description: Multifocal CONTROL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS Multifocal
Description: Multifocal CONTROL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS MAX 1-Day Multifocal
Description: Multifocal TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS MAX 1-Day Multifocal
Description: Multifocal TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS 1-Day for Astigmatism
Description: Toric CONTROL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS 1-Day for Astigmatism
Description: Toric CONTROL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A based contact lens (toric) with new UV/HEV filter
Description: Toric TEST
Study: NCT04612348

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Point of care ultrasound to measure gastric contents.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Point of care ultrasound to measure gastric contents.
Study: NCT05102409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25%)
Description: Reproxalap Ophthalmic Solution (0.25%) dosed once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xiidra® (5% lifitegrast ophthalmic solution)
Description: Xiidra® (5% lifitegrast ophthalmic solution) dosed once
Study: NCT06397963

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GT307 injection
Description: GT307 injection to treat solid tumours
Study: NCT05601544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A based contact lens (toric) with new UV/HEV filter
Description: Toric TEST